Overview Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers Status: Not yet recruiting Trial end date: 2024-05-01 Target enrollment: Participant gender: Summary TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody. Phase: Phase 1 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.